Rosacea 
                     Rosacea: Overview, Epidemiology, Treatment Market, Emerging Drugs and Key players
Rosacea is a characteristic condition that affects the skin by causing facial erythema or redness.
Around one in 10 people in the world is affected by rosacea.
How has Rosacea impacted people's lives?
Some of the key facts of the report
1. The total Rosacea prevalent population in the 7MM was 47,634,256 in 2017. 
2. The prevalence of Rosacea was found in the United States with 16,652,170 cases in 2017.
3. Germany had a prevalent population of Rosacea with 8,383,943 cases in 2017.
4. France had Rosacea prevalent population of 6,082,002 cases in 2017.
5. Italy had Rosacea prevalent population with 3,217,083 cases in 2017.
How will Disease transform Rosacea Market?
The current therapeutic landscape of Rosacea can be divided into four major categories based on
the route of administration and the approved usage for the condition. These are topical retinoids,
topical antibiotics, oral-tetracycline class antibiotics (TCAs), and oral retinoids. 
Among Topical therapies, topical retinoids mainly include Tretinoin, Tazarotene, Adapalene, and
Clindamycin/tretinoin, and several others are used to reduce erythema, papules and pustules, and
telangiectasias.  Among  these,  Tretinoin  has  the  lowest  cost  and  most  commonly  prescribed
topical retinoid, accounting for majority of the population.
Topical antibiotics, such as metronidazole (e.g. Metrolotion), clindamycin, erythromycin, azelaic
acid  (e.g.  Fincea),  benzoyl  peroxide,  benzoyl  peroxide/clindamycin,  benzoyl
peroxide/erythromycin, sulfacetamide, and sulfacetamide/sulfur, are applied directly to the skin
to kill bacteria on the surface of skin. 
The US FDA approved  drugs for Rosacea include Rhofade (topical oxymetazoline), Mirvaso
(brimonidine)  topical  gel,  Finacea  (azelaic  acid)  Foam,  Oracea  (doxycycline),  Soolantra
(ivermectin 1% cream), and MetroGel (metronidazole) gel.
The  key  driver  for  the  surge  in  Rosacea  market  size is  the  expected  launch  of  emerging
therapies and increasing Rosacea prevalence. 
Which biotechnical companies are developing Rosacea drugs? 
The dynamics of  Rosacea market is anticipated to change in the coming years owing to the
expected launch of emerging therapies during the forecasted period of 2020‒2030. There are
presently  several   Rosacea   emerging  therapies  focused  on  the  treatment  of  Rosacea  that
includes,  FMX103  (Foamix  Pharmaceuticals),  Epsolay  (Sol-Gel  Technologiesl),  ACU-D1
(Accuitis),  HY01  (Hovione  Scientia  Limited),  AFX-4031  (Afecta  Pharmaceuticals),  and
AOB103 (AOBiome).